Expertise in
12
conditions

Ulrich B. Keller

Oncology And Cancer Immunology
Berlin, BE, DE 
Expertise in
12
conditions
Oncology And Cancer Immunology
Berlin, BE, DE 

Overview

Ulrich Keller practices practicing medicine in Berlin, Germany.

Mr. Keller is highly rated in 12 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 305 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Oncology and Cancer Immunology
Berlin, BE, Germany
Other Locations
Munich, BY, Germany
Essen, NW 45122, Germany
Heidelberg, BW, Germany
Fuerstenfeldbruck, BY, Germany
Garching Bei Munchen, BY, Germany
Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

305 Total Publications

Blinatumomab in refractory SLE-associated immune thrombocytopenia.
Blinatumomab in refractory SLE-associated immune thrombocytopenia.
Journal: Annals of the rheumatic diseases
Published: July 01, 2026

Frequently Asked Questions about Ulrich B. Keller

Is Ulrich B. Keller a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Ulrich B. Keller is classified as an Distinguished expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ulrich B. Keller participate in research or clinical trials?

Yes. Ulrich B. Keller has published 305 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Ulrich B. Keller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keller's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile